Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is an open label, multicenter phase 2 study. The primary objective of the study is
to determine the efficacy of brentuximab vedotin in patients treated by gemcitabine for
relapsed or refractory peripheral T-cell lymphoma in term of overall response rate assessed
after 4 cycles of treatment according to the international response criteria for malignant
lymphoma (Lugano Classification 2014 - CT-Based Response).